Rock Springs Capital Management LP Bluebird Bio, Inc. Transaction History

Rock Springs Capital Management LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $915,600 - $2.22 Million	-35,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$46.96 - $61.67 $563,520 - $740,040	-12,000 Reduced 25.53%	35,000 $3.07 Million
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $151,680 - $210,420	2,000 Added 4.44%	47,000 $5.98 Million
Q4 2018 Feb 14, 2019	SELL	$59.1 - $93.26 $443,250 - $699,450	-7,500 Reduced 14.29%	45,000 $4.46 Million
Q3 2018 Nov 14, 2018	BUY	$88.86 - $117.49 $666,450 - $881,175	7,500 Added 16.67%	52,500 $7.67 Million
Q4 2017 Feb 14, 2018	BUY	$81.25 - $130.7 $812,500 - $1.31 Million	10,000 Added 28.57%	45,000 $8.02 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $2.02 Million - $3.2 Million	35,000	35,000 $4.81 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.